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Abstract
Objective To assess whether the START (STrAtegies for RelatTives)
intervention added to treatment as usual is cost effective compared with
usual treatment alone.
Design Cost effectiveness analysis nested within a pragmatic
randomised controlled trial.
Setting Three mental health and one neurological outpatient dementia
service in London and Essex, UK.
Participants Family carers of people with dementia.
Intervention Eight session, manual based, coping intervention delivered
by supervised psychology graduates to family carers of people with
dementia added to usual treatment, compared with usual treatment
alone.
Primary outcome measures Costs measured from a health and social
care perspective were analysed alongside the Hospital Anxiety and
Depression Scale total score (HADS-T) of affective symptoms and quality
adjusted life years (QALYs) in cost effectiveness analyses over eight
months from baseline.
Results Of the 260 participants recruited to the study, 173 were
randomised to the START intervention, and 87 to usual treatment alone.
Mean HADS-T scores were lower in the intervention group than the
usual treatment group over the 8 month evaluation period (mean
difference −1.79 (95% CI −3.32 to −0.33)), indicating better outcomes
associated with the START intervention. There was a small improvement
in health related quality of life as measured by QALYs (0.03 (−0.01 to
0.08)). Costs were no different between the intervention and usual
treatment groups (£252 (−28 to 565) higher for START group). The cost
effectiveness calculations suggested that START had a greater than
99% chance of being cost effective compared with usual treatment alone
at a willingness to pay threshold of £30 000 per QALY gained, and a
high probability of cost effectiveness on the HADS-T measure.
Conclusions The manual based coping intervention START, when
added to treatment as usual, was cost effective compared with treatment
as usual alone by reference to both outcome measures (affective
symptoms for family carers, and carer based QALYs).
Trial Registration ISCTRN 70017938
Correspondence to: M Knapp m.knapp@lse.ac.uk
Appendix A and B (as supplied by the author) (see http://www.bmj.com/content/347/bmj.f6342?tab=related#webextra)
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Introduction
England’sNational Dementia Strategy1 emphasised that “Family
carers are the most important resource available for people with
dementia” (p 12), and urged full implementation of theCarers’
Strategy.2 There was then, just as there is now, little prospect
that state funded services will reduce reliance on unpaid family
and other carers over the coming decades. Population ageing
will mean substantial growth in the number of people with
dementia, with rapidly escalating costs for health and social
care systems,3while macroeconomic pressures are leadingmany
governments to rein in public spending.
In 2010, an updatedCarers’ Strategywas published4; it included
recognition that “Caring can be very rewarding and fulfilling
but it can also be emotionally and physically draining without
recognition and practical and emotional support” (p 26). Among
the health consequences for carers, anxiety and depression are
highly prevalent.5 For this reason, the clinical guideline for
dementia issued by what was at the time the National Institute
for Health and Clinical Excellence (NICE) and the Social Care
Institute for Excellence6 recommended that “Carers of people
with dementia who experience psychological distress and
negative psychological impact should be offered psychological
therapy, including cognitive behavioural therapy, conducted by
a specialist practitioner” (p 40). However, NICE noted the
paucity of evidence in this area and recommended further
research to address the question: “For carers of people with
dementia, is a psychological intervention cost effective when
compared with usual care?” (p 45).
We conducted a randomised controlled trial to examine the
effectiveness and cost effectiveness of a manual based therapy
delivered by psychology graduates without clinical qualifications
to family carers of people with dementia. The intervention,
based on the Coping with Caring programme developed in the
United States,7 8was added to treatment as usual, and compared
with treatment as usual alone. In a companion paper, we report
the findings on clinical effectiveness9; the aim of this paper is
to report the findings on cost effectiveness.
Methods
Setting
Carers in the trial were recruited from memory services in two
mental health trusts (Camden and Islington Foundation Trust
and North Essex Partnership Foundation Trust), the North East
London Foundation Trust Admiral nurse service (specialist
nurses for family carers of people with dementia), and a tertiary
service whose referrals include a high rate of people with young
onset dementia (the Dementia Research Centre, National
Hospital for Neurology and Neurosurgery).
Participants
Family carers were eligible for inclusion in the trial if they
provided support at least weekly to patients with dementia
referred in the previous year (and who were not living in 24
hour care); if they identified themselves as the primary carer;
if they gave informed consent to the trial; if they were not
currently participating in another study because of their role as
a family carer; if they did not themselves have dementia; and
if they lived no more than 1.5 hours travelling time from the
researchers’ base at University College London.
Design
The study was a pragmatic, multicentre, randomised controlled
trial with nested cost effectiveness analysis. As described in the
companion paper,9 eligible family carers were randomised either
to the manual based therapy delivered by psychology graduates
without clinical qualifications (hereafter referred to as the
START intervention) added to treatment as usual, or to treatment
as usual alone. Randomisation was conducted using an online
computer generated system to conceal allocation, stratified by
site using random permuted blocks. An allocation ratio of 1 to
2 (usual treatment to intervention) allowed for potential
clustering effects.10 It was not possible to blind carers to
allocation, but outcome assessors were blind to randomisation
status. Sample size was calculated on the basis of the power
required to demonstrate differences in one of the effectiveness
measures and not on the basis of costs or cost effectiveness.
Treatment as usual
Treatment as usual was based around the person with dementia,
and could include medical, psychological, and other health
services and social care services. In each site, treatment, care,
and support aimed to be consistent with NICE guidelines.6
Therapy intervention
The individual therapy programme was based on Coping with
Caring,7 8 adapted for use in the UK, and was added to usual
treatment. Eligible family carers received the therapy over eight
sessions at a location chosen by the carer (usually their own
home), without the person with dementia in the room. If the
carer did not speak English fluently, the therapy was carried out
with an interpreter. The sessions were delivered by psychology
graduates with no clinical training but trained to deliver the
intervention by adhering to the manual. A clinical psychologist
(PR, one of the authors) met with each team of therapists for
1.5 hours of group clinical supervision every two weeks and
was also available for individual consultation as needed by the
therapists. Each carer had a manual and was given a compact
disc to guide relaxation exercises. Further details are given by
Livingston et al.9
Outcome measures
Assessments of each carer and each person with dementia were
carried out at baseline before the intervention, and at four
months and eight months after randomisation. Baseline
assessments covered sociodemographic characteristics of both
the carer and the person with dementia (including age, sex,
ethnicity, relationship to person with dementia, level of
education, last occupation, and living situation).
The primary clinical outcome for the carer was affective
symptoms assessed with the self completed Hospital Anxiety
and Depression Scale,11 for which the total score (HADS-T)
ranges from 0 to 42 (higher scores indicating more affective
symptoms). The HADS has two subscores, each ranging from
0 to 21: HADS-D (depression) and HADS-A (anxiety).
Carer generic health-related quality of life was rated using the
EuroQol (EQ-5D).12 Other outcome measures used in the
economic evaluation (in each case when adjusting analyses for
baseline covariates) were:
• Zarit Burden Interview,13 a 22 item, self reported
questionnaire used to assess carer burden, with scores
ranging from 0 to 88 (higher scores indicate greater burden)
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• Brief COPE,14 a self completed measure of carer coping
strategies, with subscales measuring problem focused,
emotion focused, and dysfunctional coping;
• For the person with dementia but completed by carers, the
Neuropsychiatric Inventory (NPI),15 with 12
neuropsychiatric symptom domains scored and summarised
as a single continuous score (higher scores indicating worse
symptoms).
Service use and costs
Data on services used and support received by the carer and the
person with dementia were collected using an adapted version
of the Client Service Receipt Inventory16 at baseline
(randomisation), four months, and eight months. On each
occasion, the carer was asked to report service use over the
previous four months. For the present analyses, our focus is on
service use by the carer. This inventory sought to cover all
services, including (but not limited to) inpatient stays, outpatient
attendances, day hospital treatment, visits to social clubs, meals
at lunch clubs, daycare visits, and hours spent in contact with
community based professionals (such as community teams for
older people, community psychologists, community
psychiatrists, general practitioners, nurses (either practice,
district or community psychiatric), social workers, occupational
therapists, paid home help or care workers, and
physiotherapists).
Frequency and intensity of service contacts were multiplied by
unit costs to estimate total carer related health and social care
costs. Unit costs were obtained from publicly available sources
and set at 2009-10 prices: National Health Service Schedule of
Reference Costs17 for inpatient and outpatient attendances; the
Personal Social Services Research Unit annual volume18 for
most other services; and voluntary sector bodies for a small
number of services used by a few carers (details available from
the corresponding author).
The cost of the START intervention was calculated using data
on time spent by therapists in training and supervision with a
clinical psychologist, and contacts that therapists had with carers
in delivering the intervention. Cost per hour of contact for
therapists and supervising clinical psychologist were based on
figures in the Personal Social Services Research Unit volume,18
taking the midpoint of the relevant scales and including
employer costs (national insurance and superannuation
contributions) and appropriate overheads (capital,
administration, and managerial, including recruitment costs).
We added costs for the relaxation compact disks based on the
market rates for copying and delivering.
Cost effectiveness
The economic research question was whether the START
intervention (manual based coping) was cost effective when
added to usual treatment in reducing family carer depression
and anxiety symptoms and enhancing carer health-related quality
of life over an eight month period.
The cost effectiveness analysis was conducted from a health
and social care perspective. Health and social care costs from
over the eight month period after randomisation were examined
alongside HADS-T (at eight month assessment) and quality
adjusted life years (QALYs, over eight months) in turn, the
latter calculated from the EQ-5D by applying societal weights.19
Statistical analysis
We analysedHADS-T andQALYdifferences between START
and usual treatment using a multilevel mixed effects model to
account for therapist clustering in the intervention arm and
repeated measures at four and eight months. For the HADS-T
analysis, we adjusted for baseline HADS-T, centre, carer age
and sex, carer burden (ZARIT), and neuropsychiatric symptoms
(NPI) of the person with dementia. For the QALY analyses we
adjusted for the same baseline variables, except substituting
QALY for HADS-T.
We analysed differences in health and social care cost between
START and usual treatment by regressing total cost on treatment
allocation, baseline costs, centre, carer age and sex, carer burden
(ZARIT), and care recipient neuropsychiatric symptoms (NPI).
We used a linear multilevel regression model to account for
therapist clustering in the intervention arm and repeated
measures for each individual. Non-parametric bootstrapping
was used to estimate 95% confidence intervals for mean costs.
Significance (P<0.05) was judged where the bias-corrected
confidence intervals of between-group change score excluded
zero.
All analyses were conducted on an intention-to-treat basis, but
carers were excluded if data were missing at both four and eight
months. If an individual’s data were available at four months
but not at eight months, or vice versa, their partial data were
used in the analysis. Because the estimation of QALYs requires
data at each time point, only complete cases were included in
the cost effectiveness analysis. No imputation was conducted.
Each incremental cost effectiveness ratio was calculated as the
difference in the cost of START and usual treatment divided
by the difference in outcome (measured byHADS-T orQALYs).
Cost effectiveness acceptability curves were plotted to locate
the findings of the economic evaluation in their wider decision
making context. The cost effectiveness acceptability curve
illustrates the probability that the START intervention would
be seen as cost effective compared with usual treatment across
a range of hypothesised values placed on incremental outcome
improvements (willingness to pay by health and social care
system decision makers). Each cost effectiveness acceptability
curve was derived using a net benefit approach.Monetary values
of incremental effects and incremental costs for each case were
combined, and net monetary benefit derived as:
Net monetary benefit=λ×(effectb−effecta)−(costb−costa)
where λ is willingness to pay for a one point difference in the
outcome measure (HADS-T or QALYs), and subscripts a and
b denote usual treatment and START, respectively.We explored
a range of willingness-to-pay values for each outcome.Wewere
able to account for sampling uncertainty and make adjustments
as necessary in the primary analyses and sensitivity analyses.
We also plotted the confidence intervals around net monetary
benefit to estimate the impact of uncertainty.
Sensitivity analysis
Sensitivity analyses were used to assess robustness of our results.
In sensitivity analyses we examined the extent to which
individuals with missing outcome data varied by baseline
characteristics. This was investigated separately for each
outcome using logistic regression. The first step was to model
a binary variable (missing versus not missing) in bivariate
logistic regression with each baseline demographic variable.
Those variables identified as significantly associated with
missing were then used in multivariate logistic regression to
determine which remained significant. The main analyses were
then repeated, adjusting for those factors found to be associated
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with “missingness” on each outcome. For the analysis of
HADS-T, the variables found to be associated with missingness
were: patient living with carer, relationship to carer, carer having
children at home, patient ethnicity, and COPE dysfunction score.
For the QALY outcome, the carer’s work situation (employed
versus unemployed) and ethnicity were associated with
missingness.
A second sensitivity analysis adjusted for imbalances in baseline
characteristics between the treatment groups that occurred
despite randomisation (that is, adjusting for carers’ work
situation, relationship to carer, and patients’ and carers’
education and living situation). These analyses were chosen so
as to be consistent with those used in the effectiveness paper.9
All statistical analyses followed a predefined analysis plan and
were carried out using STATA version 12.20
Results
Participants
Of the 260 carers who consented to enter the randomised trial,
173 were randomised to START and 87 to usual treatment. The
groups were broadly similar at baseline by reference to
demographic and clinical characteristics of both people with
dementia and carers, except that carers in the START group
were slightly older; more likely to be retired, male, unmarried,
without qualifications or tertiary education, and living with the
person with dementia; more likely to have case level anxiety;
and had slightly lower HADS anxiety scores. Further details of
trial participants are given by Livingston et al.9
Ten therapists (seven female) delivered the intervention,
supporting between 11 and 21 carers each. Therapists were aged
in their 20s or 30s, and were psychology graduates.
Service use and costs
Carers used a wide range of health and social care services over
the eight month period, as can be seen from the summary
statistics in table 1⇓. We did not impute individual items of
service use, and means are presented for non-missing cases
only. Outpatient hospital and general practice services were
used by high proportions of participants.
These patterns of service use were weighted by their unit costs,
which are detailed in the final two columns of table 1⇓. Mean
costs—grouped into outpatient, community, and other
services—are given in table 2⇓. The table distinguishes the
START and usual treatment groups and reports figures for two
time periods, the four month period between baseline and the
four month assessment, and the four month period between the
four month and eight month assessments. Although the number
of users of outpatient services was higher in the intervention
group (table 1⇓), their average outpatient service cost was lower
as they used outpatient services less frequently than people in
the usual treatment group.
The right hand column of table 2⇓ shows the difference in costs
between the START and usual treatment groups across the
whole evaluation period of eight months. Excluding the direct
cost of the intervention itself, mean costs over the study period
(1-8 months) were £558 in the START group and £625 in the
usual treatment group. After adjustment for baseline
characteristics (see above), the standardised difference was £14,
with the 95% confidence interval (−239 to 211) suggesting that
there was no significant difference in costs between the two
groups. For purposes of comparison, scores on the two outcome
measures used in the economic evaluation are included towards
the bottom of table 2⇓.
Based on the time spent by the 10 therapists in delivering
one-to-one therapy to carers, their own training sessions (40
sessions of 2.5 hours over a six week period), time spent making
telephone calls to participants, time spent writing up notes, and
supervision of the therapists by the clinical psychologist (1.5
hours each per week for eight weeks), we calculated that the
mean cost per session per carer was £36. Adding in the cost of
the relaxation compact disks (which totalled £284), the overall
mean direct intervention cost averaged £232.15 per carer.
Including the cost of intervention itself in the comparison
between the groups, and now adjusting for baseline variables,
costs for the START group were slightly but not significantly
higher than for the usual treatment group. The mean cost
difference was £252 (95% confidence interval −28 to 565) for
sample members on the EQ-5D, and £247 (0 to 569) for sample
members on the HADS-T measure (table 3⇓).
Cost effectiveness
Results from the net benefit regression using the two outcomes
examined in the economic evaluation (QALYs and HADS-T
score) are summarised, and the incremental cost effectiveness
ratios (ICERs) reported, in table 3⇓. The cost and outcome
differences are obtained after adjustment for baseline
characteristics and are influenced slightly by size of sample
with complete data for each outcome.
Carers who received the START intervention (manual based
coping strategy in addition to treatment as usual) generated
slightly, though not statistically significantly, higher health and
social care system costs but enjoyed significantly better
outcomes, whether measured in terms of health-related quality
of life (QALY) or affective symptoms (HADS-T). Whether
these results imply that START is cost effective compared with
usual treatment depends on the decision maker’s willingness to
pay for these gains in quality of life and affective symptoms.
To aid discussion of willingness to pay, we computed the ICERs.
We also plotted the associated cost effectiveness acceptability
curves and examined the confidence intervals around net
monetary benefit.
Looking first at QALY as the outcome, themean cost per QALY
gained was £6000. The acceptability curve is shown in figure
1⇓, illustrating the probability of cost effectiveness for each of
a number of different hypothesised values of willingness to pay.
At the £20 000 per QALY threshold associated with NICE
recommendations,21 the probability that the START intervention
would be seen as cost effective was 93%, and at the higher NICE
threshold of £30 000 it was 99%. The 95% confidence intervals
around net monetary benefit suggest that there is a strong
likelihood that START is cost effective at the £30 000 threshold
(see appendix B on bmj.com).
For the other outcome measure, the HADS-T measure of
affective symptoms, mean cost per one point difference on the
HADS-T scale was £118. The cost effectiveness acceptability
curve for this outcome measure is shown in figure 2⇓. We are
not aware of any previously suggested monetary thresholds for
gauging cost effectiveness on the HADS scale. However, if we
assumed a willingness to pay of £500, the probability that the
START intervention would be seen as cost effective would be
95%.We can also refer to a previous suggestion that a minimally
important clinical difference on the HADS-T scale is 1.6. The
mean cost of achieving such a change with START would be
£189.
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Sensitivity analysis
The first sensitivity analysis adjusted for significant baseline
differences on demographic and clinical predictors of missing
values. The results were similar to those from the primary
analyses and are summarised in the first column of data in table
4⇓. Themean ICER values are now £5452 per additional QALY,
and £107 per one point difference in HADS-T score. Figure 3⇓
shows the cost effectiveness acceptability curve with QALY as
the outcome measure: at the lower bound NICE threshold
(£20 000), the START intervention has an approximately 95%
likelihood of being seen as cost effective, rising to 98% at the
£30 000 threshold.
The second sensitivity analysis adjusted for imbalances in
baseline characteristics. The results were again quite similar to
those from the primary analyses and are summarised in the
second column of data in table 4⇓. The mean ICER values from
this further analysis are £5756 per additional QALY, and £112
per one point difference in HADS-T score. The cost
effectiveness acceptability curve with QALY as the outcome
measure is shown in figure 4⇓: at the lower bound NICE
threshold (£20 000), the START intervention has a 93%
likelihood of being seen as cost effective, rising to 98% at the
£30 000 threshold.
The confidence intervals around net monetary benefit for these
two sensitivity analyses, taking into account uncertainty in the
estimation, suggest a degree of caution in concluding that
START is necessarily cost effective.
Discussion
Principal findings
We examined whether eight sessions of manual based coping
strategy therapy, delivered over 8-14 weeks by supervised
psychology graduates to family carers of people with dementia,
added to treatment as usual, was cost effective compared with
treatment as usual alone. Over the eight month evaluation period,
the START intervention was found to have a high probability
of being seen as cost effective by reference to both primary
outcomemeasures examined: improvements in carers’ affective
symptoms and gains in carers’ quality adjusted life years. The
sensitivity analyses, considering alternative approaches to the
analysis, suggest a more cautious conclusion as to the cost
effectiveness of START.
Strengths and limitations of the study
Each carer recruited to the study was scheduled to have eight
sessions with the therapist, but some carers had fewer sessions.9
Although this was taken into account in calculating the costs of
the intervention, the impact that different numbers of sessions
might have had on carers’ outcomes was not the focus of this
study.
The evaluation was conducted from a health and social care
perspective, and concentrated on outcomes experienced by
carers. We did not, therefore, measure the costs of treatment
and care services used by the individuals with dementia who
were being supported by these carers, nor did we attach
monetary values to the time spent by carers in providing support
to their relatives. We will examine those wider cost measures,
and the outcomes experienced by the patients with dementia,
in later work. We will also examine longer term cost
effectiveness in later work, as participants in this study are being
followed for longer than the eight months considered in this
paper.
Sample size for the study design was calculated on the basis of
the power required to demonstrate differences in one of the
effectiveness measures and not on the basis of costs or cost
effectiveness. Although it would have been preferable for the
study also to have been powered on an economic variable, this
would have required a considerable increase in sample size
given that economic measures tend to be highly skewed.22 In
turn, this would have had implications for both the research
budget and ethics, since it would have been necessary to recruit
participants beyond the point where clinical dominance has been
determined. We used cost effectiveness acceptability curves to
represent the uncertainty in the estimation of the incremental
cost effectiveness ratio.23
Comparison with other studies
There is little previous evidence on the cost effectiveness of
psychosocial interventions for carers of people with dementia:
a recent review found some evidence that such interventions
could lead to greater improvements in outcome and also generate
cost savings.24However, only one of the studies covered by that
review employed a similar therapeutic approach to the START
intervention: Nichols et al25 examined the cost effectiveness of
a modular multicomponent intervention delivered in carers’
homes, with three sessions by telephone, supplemented by five
group sessions (five or six carers in each) delivered by
telephone. Focusing on hours of care giving, the authors found
a significant difference over the six month study period, with
carers in the intervention group having more time to dedicate
to activities unrelated to care giving, which has potentially
positive impacts on emotional wellbeing and quality of life.26 27
Implications for policy and practice
The encouraging outcomes from the START trial suggest that
a manual based therapy for family carers of people with
dementia, delivered by psychology graduates without clinical
qualifications, was effective asmeasured on several dimensions.9
From the present paper, the intervention is also likely to be
perceived as cost effective by reference to NICE thresholds:
there is therefore both a clinical and an economic case for
supporting carers of people with dementia using such an
approach. This cost effectiveness advantage arises because the
intervention improved carer outcomes while not significantly
increasing overall costs, with the additional cost of the
intervention being partly counterbalanced by a reduction in
service related costs.
The cost effectiveness finding is driven more by the outcome
differences between the groups than the cost difference; for
example, at the eight month point, carers in the control group
were four times more likely to have clinically significant
depression than carers who had received the START
intervention.9 Carers in the intervention group were given
information on where to get emotional support and were given
techniques to help them to better understand behaviours of the
person they cared for, manage behaviour, change unhelpful
thoughts, promote acceptance, relax, and engage in meaningful
activities. Previous studies have shown that counselling can
reduce depression among carers of people with Alzheimer’s
disease,28 and long term intensive social work support has the
potential to reduce carer burden.29
Many countries, including the UK, face rapidly growing
numbers of elderly people, while policy frameworks continue
to assume that families will remain the frontline providers of
(unpaid) care and support. Most people with dementia also
prefer to receive support from family members. In these
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circumstances, an intervention that is cost neutral, even over a
relatively short period, and which significantly improves carer
mental health and quality of life should be made more widely
available.
Conclusion
The START intervention is cost effective when added to usual
care, when costs are measured from the perspective of the health
and social care system, and when outcomes are measured in
terms of carers’ affective symptoms and health related quality
of life over an eight month period.
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What is already known on this subject
Family carers are the mainstay of dementia care in the UK
There is little evidence on interventions to support carers that have been shown to be cost effective
What this study adds
Looking at health and social care services used by carers, the START intervention is not more expensive than usual care
The START intervention is cost effective when added to usual care by reference to reductions in carer affective symptoms and
improvements in carer health related quality of life.
Tables
Table 1| Carers’ use of health and social care services at baseline and at four months and eight months of evaluation period. Values are
percentages (numbers) of participants unless stated otherwise
Unit
Unit
cost (£*)
8 Months4 MonthsBaseline
Service
Intervention
(n=134)
Usual
treatment
(n=71)
Intervention
(n=150)
Usual
treatment
(n=75)
Intervention
(n=173)
Usual
treatment
(n=87)
Per attendance†18-29637.3 (50)28.2 (20)38.7 (58)32.0 (24)37.0 (64)33.3 (29)Outpatient hospital
services
Community based
services:
Per hour313.7 (5)2.8 (2)6.0 (9)2.6 (2)3.5 (6)5.7 (5)Admiral nurse
Per hour2217.2 (23)12.7 (9)11.3 (17)9.3 (7)13.9 (24)5.7 (5)Chiropodist
Per hour341.5 (2)11.3 (8)2.7 (4)9.3 (7)2.3 (4)8.0 (7)Counsellor
Per attendance‡8733.6 (45)36.6 (26)30.7 (46)29.3 (22)30.6 (53)27.6 (24)Dentist
Per consultation2848.5 (65)47.9 (34)50.0 (75)53.3 (40)54.3 (94)54.0 (47)General practitioner
Per hour31.5 (2)0 (0)0 (0)1.3 (1)1.2 (2)1.1 (1)NHS Direct
Per hour2918.7 (25)21.1 (15)15.3 (23)8.0 (6)16.8 (29)17.2 (15)Optician
Per hour150 (0)1.4 (1)0.7 (1)0 (0)0.6 (1)1.1 (1)Outreach worker
Per weekday
hour
211.5 (2)1.4 (1)1.3 (2)4.0 (3)1.7 (3)2.3 (2)Home care worker or
care attendant
Per hour222.2 (3)0 (0)0 (0)1.3 (1)0.6 (1)0 (0)Physiotherapist
Per hour1740.7 (1)1.4 (1)0.7 (1)0 (0)0.6 (1)0 (0)Hygienist
Per session§1750 (0)0 (0)0 (0)0 (0)0.6 (1)0 (0)Company medical
check-up
Per hour370 (0)0 (0)0 (0)0 (0)0.6 (1)1.1 (1)Nurse (advanced)
Per hour390 (0)0 (0)0.7 (1)0 (0)0.6 (1)0 (0)Occupational
therapist
Per hour220 (0)0 (0)0 (0)0 (0)0.6 (1)0 (0)Community
psychiatrist
Per hour265.2 (7)0 (0)4.7 (7)2.6 (2)2.3 (4)6.9 (6)Practice nurse
Per journey¶40-2460 (0)0 (0)0.7 (1)0 (0)0 (0)0 (0)Ambulance transport
Per hour220 (0)0 (0)0.7 (1)0 (0)0 (0)0 (0)Dietician
Per hour3.5-17413.4 (18)12.7 (9)14.0 (21)22.7 (17)9.8 (17)16.1 (14)Other services
*Costs at 2009-10 prices.
†Unit cost varies with clinical specialty; for details see appendix A on bmj.com.
‡Attendance assumed to last 30 minutes.
§Session lasts 30 minutes.
¶£40 for transport to hospital; £246 for emergency transport.
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Table 2| Health and social service costs and outcomes used in the economic evaluation at 4 and 8 months for carers in the START
intervention and usual treatment groups, and differences between the groups. Values are means (standard deviations) unless stated
otherwise
Difference (95% CI) for
intervention v usual
InterventionUsual treatment
Costs and
outcomes 5–8 months1–4 months5–8 months1–4 months
treatment over 1–8
months*
−14 (−239 to 211)
(n=193)
262 (598)296 (1006)244 (450)381 (1102)Costs (£†):
−42 (−118 to 34)99 (237)99 (183)125 (385)140 (428)Outpatient
−7 (−34 to 19)96 (153)101 (180)110 (153)107 (148)Community
27 (−151 to 205)68 (461)96 (845)9 (36)134 (1028)Other
Outcomes:
−1.79 (−3.22 to −0.37)
(n=220)
12.9 (7.9)12.4 (7.4)14.9 (8.0)14.3 (7.4)HADS-T‡
0.03 (−0.01 to 0.08)
(n=212)
0.76 (0.24)0.77 (0.22)0.79 (0.14)0.77 (0.23)EQ-5D
HADS-T= Hospital Anxiety and Depression Scale total score. EQ-5D=EuroQol health-related quality of life scale.
*Adjusted for baseline variables
†Costs at 2009-10 prices.
‡HADS-T scores and difference are slightly different from those in related clinical effectiveness paper9 because different versions of STATA statistical software
were used for the analyses.
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Table 3| Differences in treatment and cost effects (with 95% confidence intervals corrected for bias) and incremental cost effectiveness
ratios between the START intervention and usual treatment groups over 8 month evaluation period
Mean differences (95% CI) and ICERsEffect
With QALY as outcome (n=177*)
252 (−28 to 565)Incremental health and social care costs (£†)
0.042 (0.015 to 0.071)Incremental QALY gain
6000ICER (£ per QALY)
With HADS-T as outcome (n=191‡)
247 (0 to 569)Incremental health and social care costs (£†)
2.10 (0.51 to 3.75)Incremental HADS-T change
118ICER (£ per unit change on HADS-T)
ICER=Incremental cost effectiveness ratio. QALY=quality adjusted life year. HADS-T=Hospital Anxiety and Depression Scale total score.
*Sample size based on complete data for QALY and cost measures.
†Costs at 2009-10 prices.
‡Sample size based on complete data for HADS-T and cost measures.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;347:f6342 doi: 10.1136/bmj.f6342 (Published 25 October 2013) Page 9 of 12
RESEARCH
Table 4| Sensitivity analyses of differences in treatment and cost effects (with 95% confidence intervals) and incremental cost effectiveness
ratios between the START intervention and usual treatment groups over 8 month evaluation period
Mean differences (95% CI) and ICERs
Effect Adjusting for baseline imbalances
Adjusting for significant demographic and clinical predictors of
missing values
With QALY as outcome (n=177*)
236 (−101 to 617)229 (−94 to 552)Incremental health and social care costs (£†)
0.041 (0.012 to 0.071)0.042 (0.014 to 0.070)Incremental QALY gain
57565452ICER (£ per QALY)
With HADS-T as outcome (n=191‡)
231 (−46 to 583)226 (−74 to 525)Incremental health and social care costs (£†)
2.07 (0.44 to 3.90)2.11 (0.41 to 3.81)Incremental HADS-T change
112107ICER (£ per unit change on HADS-T)
ICER=Incremental cost effectiveness ratio. QALY=quality adjusted life year. HADS-T=Hospital Anxiety and Depression Scale total score.
*Sample size based on complete data for QALY and cost measures.
†Costs at 2009-10 prices.
‡Sample size based on complete data for HADS-T and cost measures.
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Figures
Fig 1 Cost effectiveness acceptability curve: START intervention (manual based coping strategy therapy) versus treatment
as usual; health and social care perspective, with effectiveness measured in quality adjusted life year (QALY) gain, over
eight months
Fig 2 Cost effectiveness acceptability curve: START intervention (manual based coping strategy therapy) versus treatment
as usual; health and social care perspective, with effectiveness measured on the Hospital Anxiety and Depression Scale
total score (HADS-T), over eight months
Fig 3 Cost effectiveness acceptability curve: START intervention versus treatment as usual; health and social care
perspective, with effectiveness measured in quality adjusted life year (QALY) gain, over eight months, following sensitivity
analysis adjusting for significant predictors of missing values
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Fig 4 Cost effectiveness acceptability curve: START intervention versus treatment as usual; health and social care
perspective, with effectiveness measured in quality adjusted life year (QALY) gain, over eight months, following sensitivity
analysis adjusting for baseline imbalances
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